Skip to content

Total debt at other companies

Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$9.11M-5.7%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$445.39M+32.2%
Pfizer logo
PfizerPFE
Merck & Co. logo
Merck & Co.MRK
Moderna logo
ModernaMRNA
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $116.3M.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s total debt?
Vaxcyte, Inc. (PCVX) reported total debt of $116.3M in Q1 2026.
How has Vaxcyte, Inc.'s total debt changed year-over-year?
Vaxcyte, Inc.'s total debt increased by 33.5% year-over-year, from $87.11M to $116.3M.
What is the long-term trend for Vaxcyte, Inc.'s total debt?
Over 5 years (2020 to 2025), Vaxcyte, Inc.'s total debt has grown at a 165.0% compound annual growth rate (CAGR), from $900K to $117.58M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.